Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma Corporation is asking shareholders to vote at its 2026 Annual General and Special Meeting on May 26, 2026 in Vancouver, BC. Holders of 196,939,679 common shares outstanding as of March 30, 2026 may vote.
Shareholders will elect five directors, consider a new 2026 Omnibus Share and Incentive Plan authorizing up to 16,300,000 common shares for equity awards, hold an advisory “say‑on‑pay” vote on named executive officer compensation, and approve the appointment of EY as independent registered public accounting firm for 2026. Materials are delivered primarily online, with voting available by mail, phone, Internet, or in person.
Whitefort Capital and related entities report beneficial ownership of 15,794,261 Arbutus Biopharma common shares, or approximately 8.1% of the class, in this amended Schedule 13D. The stake is based on 195,478,068 shares outstanding as of March 18, 2026.
The shares were purchased by Whitefort Capital Master Fund using working capital, which may include margin loans, for an aggregate purchase price of about $41,839,734 including brokerage commissions. Multiple Whitefort entities and Messrs. David Salanic and Joseph Kaplan may be deemed beneficial owners and expressly disclaim ownership of securities they do not directly own.
The amendment updates the ownership calculations and adds an exhibit listing all transactions in Arbutus Biopharma shares by the reporting persons over the prior 60 days, noting that these trades occurred in the open market unless otherwise indicated.
Arbutus Biopharma reported improved 2025 results and a transformative litigation settlement. Cash, cash equivalents and marketable securities were $91.5 million as of December 31, 2025, down from $122.6 million a year earlier as the company used $39.6 million in operating activities, partly offset by option exercises.
Total 2025 revenue rose to $14.1 million from $6.2 million, driven by recognition of previously deferred Qilu partnership revenue. Operating expenses fell sharply to $52.2 million from $82.5 million due to R&D and G&A cuts and restructuring, reducing net loss to $33.5 million, or $0.17 per share, versus $69.9 million, or $0.38 per share, in 2024.
Arbutus and Genevant reached a $2.25 billion global settlement with Moderna over lipid nanoparticle technology, including a $950 million noncontingent payment due in July 2026 and a $1.3 billion contingent payment tied to a Section 1498 appellate ruling. Arbutus will receive 20% of the noncontingent payment after litigation costs and also owns about 16% of Genevant. The company is evaluating a return of capital to shareholders after receiving its portion. Clinical updates include a total of 10 Phase 2a imdusiran patients achieving functional cure in chronic hepatitis B, with most maintaining durable responses.
Arbutus Biopharma Corporation is a clinical-stage biotech focused on chronic hepatitis B, developing imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company’s LNP delivery technology underpins major COVID-19 mRNA vaccines and is central to its strategy.
A key development is a settlement with Moderna, under which Moderna will pay an aggregate $950.0 million noncontingent lump sum to Arbutus and Genevant by July 8, 2026, plus a contingent lump sum of up to $1.3 billion tied to a limited appeal outcome. Arbutus is entitled to 20% of settlement proceeds (after litigation costs) under its Genevant license and also owns about 16% of Genevant’s common equity. The company is evaluating a potential return of capital to shareholders in the third quarter of 2026 after receiving its share of the noncontingent payment.
Arbutus continues patent litigation against Pfizer/BioNTech over alleged use of its LNP technology. It has restructured heavily, halting discovery efforts, closing its Warminster headquarters, and reducing its workforce by about 40% in 2024 and a further 57% in early 2025, incurring $12.9 million in one-time restructuring charges but significantly lowering net cash burn. As of June 30, 2025, non‑affiliate equity had an approximate market value of $472,133,611 based on a share price of $3.09, and as of March 18, 2026, there were 195,478,068 common shares outstanding.
Arbutus Biopharma and Genevant have entered a global patent settlement with Moderna totaling up to $2.25 billion. Moderna will pay $950 million as a noncontingent lump sum in July 2026 and a further $1.3 billion only if Moderna’s appeal under U.S. Section 1498 is resolved in Arbutus/Genevant’s favor or not pursued. If the appellate court finds that Section 1498 bars only some vaccine doses, the contingent amount will be prorated, and under certain later reversals Arbutus/Genevant must repay it with interest.
The agreement ends all LNP-related litigation with Moderna and includes a fully paid-up, royalty-free, irrevocable, non-exclusive worldwide license and covenant not to sue for Moderna’s SM-102–based mRNA vaccines for infectious diseases meeting specified conditions. Under Arbutus’s license with Genevant, Arbutus is entitled to 20% of settlement proceeds after litigation costs and is evaluating a potential return of capital to shareholders in the third quarter of 2026 tied to the upfront payment.
Arbutus Biopharma reported a key court ruling in its patent case against Moderna over lipid nanoparticle technology used in the COVID‑19 vaccine mRNA‑1273. The Delaware federal court held that inter partes review estoppel and issue preclusion bar Moderna from pursuing obviousness defenses against several Arbutus patents and rejected Moderna’s derivation defense to U.S. Patent No. 9,504,651. However, the judge found that Moderna’s expert evidence on enablement creates factual disputes, so Moderna may still argue that the asserted patents are not enabled at trial. The court also excluded obviousness opinions from one Moderna expert while allowing another expert’s enablement opinions to be presented to a jury.
Two Seas Capital LP and related parties reported a significant passive stake in Arbutus Biopharma Corp. As of December 31, 2025, Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi each beneficially owned 12,589,158 Arbutus common shares, representing 6.5% of the company.
The shares are held through Two Seas Global (Master) Fund LP, with 9,078,634 shares, and Two Seas LNP Opportunities (Master) Fund LP, with 3,510,524 shares. The reporting persons have sole voting and dispositive power over these shares and classify the position as held in the ordinary course of business, not to influence control of Arbutus.
Morgan Stanley and Morgan Stanley Investment Management Inc. report significant ownership of Arbutus Biopharma Corp common shares. As of the event date of 12/31/2025, Morgan Stanley is deemed to beneficially own 25,910,337 shares, representing 13.5% of the outstanding common shares.
The filing shows no sole voting or dispositive power, with voting and dispositive authority largely shared across related entities. The firms certify the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Arbutus Biopharma.
Arbutus Biopharma Corporation reported a key court decision in its patent lawsuit, brought with Genevant, against Moderna over lipid nanoparticle (LNP) technology used in Moderna’s COVID‑19 vaccine mRNA‑1273. A U.S. District Court in Delaware largely rejected Moderna’s argument that the case belongs in the Court of Federal Claims under a statute covering inventions used “for the Government,” limiting that defense to vaccine doses given directly to U.S. government employees.
The Court also held that Arbutus is barred by prosecution history estoppel from relying on the doctrine of equivalents for several “molar ratio” LNP patents, meaning it must prove literal infringement on those claims. At the same time, the judge found that disputes over whether Arbutus’s patents are invalid as indefinite must be decided by a jury and allowed expert testimony on that issue, while excluding several other experts on both sides.